Objective We aimed to perform a meta-analysis to summarize the overall evidence from
randomized controlled trials related to higher-intensity anticoagulation in hospitalized …

Background: Anticoagulation is generally used in hospitalized patients with coronavirus
disease 2019 (COVID-19) as thromboprophylaxis. However, results from different studies …

Coronavirus disease 2019 (COVID‐19) is associated with a hypercoagulable state. It has
been hypothesized that higher‐dose anticoagulation, including therapeutic‐dose and …

Background: COVID-19 patients are at high thrombotic risk. The safety and efficacy of
different anticoagulation regimens in COVID-19 patients remain unclear. Methods: We …

Background Thromboembolic events are common complications of COVID-19. Clinical study
results on safety and efficacy of anticoagulation in COVID-19 are controversial. Material and …

Purpose As no reported randomized control trials (RCTs) directly compare the three
administration doses of anticoagulants (prophylactic dose, treatment dose, and no …

Background The clinical impact of different prophylactic anticoagulation regimens among
hospitalized patients with coronavirus disease 2019 (COVID-19) remains unclear. We …

Background Anticoagulation in hospitalized COVID-19 patients has been associated with
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …

We conducted a systematic review and a meta-analysis to assess the association of
anticoagulants and their dosage with in-hospital all-cause mortality in COVID-19 patients …

Background COVID‐19 disease‐related coagulopathy and thromboembolic complication,
an important aspect of the disease pathophysiology, are frequent and associated with poor …